In line with the hypothesis that G-CSF/GM-CSF treatment is associated with the development of lung damage, Verhoef et al. reported a case of a patient who developed ARDS during treatment with rhGM-CSF for severe transfusion-dependent refractory anemia with excess of blasts [27]. The gene discussed is CSF2; the disease is anemia (phenotype).